Nucleome Therapeutics appoints experienced biotech executive Dr. Michelle Morrow as Chief Scientific Officer

Brings deep expertise in immunology, oncology and pharmacology with a strong track record of advancing innovative pipelines through discovery and translation into the clinicReflects growing momentum at Nucleome following nomination of first preclinical development candidate for lead candidate NTP464, which is progressing towards IND enabling studiesView original content:https://www.prnewswire.co.uk/news-releases/nucleome-therapeutics-appoints-experienced-biotech-executive-dr-michelle-morrow-as-chief-scientific-officer-302687866.html

en | CH0038389992 | NUCLEOME | boerse | 68935036 |